Triple negative breast cancer (TNBC) – what is it and how is it treated? Join BCF’s webinar at 7pm on Thurs 29th Feb and hear from an oncologist, a nurse and a patient on what a diagnosis of TNBC means and the choices faced by patients.
Between 10 and 15% of all breast cancers are triple negative, which means they have none of the three receptors (oestrogen, progesterone and HER2) most commonly found in breast cancer.
This affects how this type of breast cancer is treated – people with triple negative can’t receive tamoxifen, aromatase inhibitors or Herzuma/Herceptin. It can be treated with immunotherapy drugs like Keytruda, but none of these are funded in New Zealand.
This webinar looks at what a diagnosis of triple negative breast cancer means for you, what the treatment options are and the considerations and decisions patients face.
This webinar looks at what a diagnosis of triple negative breast cancer means for you, what the treatment options are and the considerations and decisions patients face.
Join this Breast Cancer Foundation webinar online on Thursday 29th at 7pm and don't forget your questions for the Q & A at the end.
